For the quarter ending 2026-03-31, ALT had $29,531K increase in cash & cash equivalents over the period. $27,134K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 38,172 | -19,014 | -41,721 |
| Stock-based compensation expense | -7,757 | 3,554 | 7,581 |
| Depreciation of property and equipment | -63 | 27 | 59 |
| Deferred income tax benefit | - | 0 | -681 |
| Accretion of discounts on short-term investments | -443 | 196 | 1,117 |
| Amortization of debt discount and costs | 47 | 113 | 58 |
| Loss on foreign currency exchange | -38 | -86 | -30 |
| Impairment loss on long-lived asset | 709 | - | - |
| Accounts receivable | 145 | 524 | -223 |
| Prepaid expenses and other assets | -3,520 | 8 | 1,895 |
| Accounts payable | -5,780 | 3,953 | 640 |
| Accrued expenses and other liabilities | -531 | 102 | -2,064 |
| Income tax and r&d incentive receivables | 2,189 | -10 | -2,697 |
| Net cash used in operating activities | 27,145 | -11,897 | -36,190 |
| Proceeds from sales and maturities of short-term investments | -103,967 | 0 | 143,589 |
| Proceeds from exercises of stock options | - | 33 | 8 |
| Purchases of short-term investments | -153,603 | 149,321 | 47,573 |
| Proceeds from term loan | - | 0 | 15,000 |
| Purchases of property and equipment | 11 | 0 | 10 |
| Payment for debt issuance costs | - | 322 | 404 |
| Net cash used in investing activities | 49,625 | -149,321 | 96,006 |
| Payments of deferred offering costs | -209 | 0 | 298 |
| Proceeds from issuance of common stock in at-the-market offerings, net | -103,346 | 39,517 | 72,571 |
| Proceeds from issuance of common stock and pre-funded warrants in direct offering, net | 70,338 | - | - |
| Proceeds from issuance of common stock from employee stock purchase plan | -114 | 121 | 170 |
| Payments for tax withholding in share-based compensation | 11 | 0 | 684 |
| Net cash provided by financing activities | -47,239 | 39,349 | 86,363 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 29,531 | -121,869 | 146,179 |
| Cash, cash equivalents and restricted cash at beginning of period | 61,278 | 36,968 | - |
| Cash, cash equivalents and restricted cash at end of period | 97,643 | 61,278 | - |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)